Page 179 - EJMO-9-2

Eurasian Journal of
Medicine and Oncology PD-1/L1 inhibitors in advanced CC: Multicenter retro

Table 1. Baseline characteristics of 192 advanced cervical patients
Characteristics Total (n=192) (%) Treatment group Control group t‑test or p‑value
(n=91) (%) (n=101) (%) Chi‑square test
Age (years)
Median (range), years 53 (22 – 82) 53 (25 – 82) 51 (22 – 80)
Mean±standard deviation 51.9±11.0 51.9±11.0 51.9±10.9 t=0.008 0.993
χ =0.985 0.321
2
>50 111 (57.8) 56 (61.5) 55 (54.5)
≤50 81 (42.2) 35 (38.5) 46 (45.5)
Histology χ =0.035 0.852
2
Squamous cell carcinoma 180 (93.8) 85 (93.4) 95 (94.1)
Adenocarcinoma 12 (6.2) 6 (6.6) 6 (5.9)
PD-L1 expression χ =13.455 0.001*
2
CPS ≥1 71 (37.0) 45 (49.5) 26 (25.7)
CPS <1 11 (5.7) 2 (2.2) 9 (8.9)
Unknown 110 (57.3) 44 (48.3) 66 (65.4)
FIGO stage 0.507
IIIC 135 (70.3) 62 (68.1) 73 (72.3)
IVA 9 (4.7) 6 (6.6) 3 (3.0)
IVB 48 (25.0) 23 (25.3) 25 (24.7)
Tumor diameter χ =0.030 0.862
2
≤4 cm 38 (28.1) 17 (27.4) (28.8)
>4 cm 97 (71.9) 45 (72.6) 52 (71.2)
Notes: Data are presented as n (%) unless otherwise specified; *indicates statistical significance at p<0.05.
Abbreviations: CPS: Combined positive score; FIGO: Federation of gynecology and obstetrics; PD-L1: Programmed death-ligand 1.

Figure 1. Flowchart of the study procedure
Abbreviations: PD-1: Programmed cell death protein 1; PD-L1: Programmed death-ligand 1.

Volume 9 Issue 2 (2025) 171 doi:10.36922/ejmo.8074